Please wait while the formulary information is being retrieved.
SOMATULINE DEPOT (LANREOTIDE ACETATE)
- Acromegaly
- Carcinoid syndrome
- Malignant gastroenteropancreatic neuroendocrine tumor
120 mg/0.5 mL subcutaneous syringe
- Inject 0.5 milliliter (120 mg) by subcutaneous route every 4 weeks
60 mg/0.2 mL subcutaneous syringe
- Inject 0.2 milliliter (60 mg) by subcutaneous route every 4 weeks
90 mg/0.3 mL subcutaneous syringe
- Inject 0.3 milliliter (90 mg) by subcutaneous route every 4 weeks
120 mg/0.5 mL subcutaneous syringe
- Inject 0.5 milliliter (120 mg) by subcutaneous route every 4 weeks
60 mg/0.2 mL subcutaneous syringe
- Inject 0.2 milliliter (60 mg) by subcutaneous route every 4 weeks
90 mg/0.3 mL subcutaneous syringe
- Inject 0.3 milliliter (90 mg) by subcutaneous route every 4 weeks
Acromegaly
- Inject 0.2 milliliter (60 mg) by subcutaneous route every 4 weeks
- Inject 0.3 milliliter (90 mg) by subcutaneous route every 4 weeks
- Inject 0.5 milliliter (120 mg) by subcutaneous route every 4 weeks
- Inject 0.4 milliliter (120 mg) by subcutaneous route every 4 weeks
- Inject 0.5 milliliter (120 mg) by subcutaneous route every 6 weeks
- Inject 0.5 milliliter (120 mg) by subcutaneous route every 8 weeks
- Inject 0.4 milliliter (120 mg) by subcutaneous route every 6 weeks
- Inject 0.4 milliliter (120 mg) by subcutaneous route every 8 weeks
Carcinoid syndrome
- Inject 0.5 milliliter (120 mg) by subcutaneous route every 4 weeks
- Inject 0.4 milliliter (120 mg) by subcutaneous route every 4 weeks
Malignant gastroenteropancreatic neuroendocrine tumor
- Inject 0.5 milliliter (120 mg) by subcutaneous route every 4 weeks
- Inject 0.4 milliliter (120 mg) by subcutaneous route every 4 weeks
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactating mother
Contraindicated
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Disease of liver
Severe
Moderate
- Biliary calculus
- Bradycardia
- Gallbladder disease
- Hyperglycemia
- Hypertension
- Hypoglycemic disorder
- Hypothyroidism
- Kidney disease with likely reduction in GFR
SOMATULINE DEPOT (LANREOTIDE ACETATE)
- Acromegaly
- Carcinoid syndrome
- Malignant gastroenteropancreatic neuroendocrine tumor
- Biliary calculus
- Dysglycemia
- Acute abdominal pain
- Anemia
- Arthralgias
- Diarrhea
- Flatulence
- Injection site sequelae
- Loose stools
- Musculoskeletal pain
- Myalgias
- Nausea
- Vomiting
- Weight loss
More Frequent
Severe
Less Severe
- Bradycardia
- Diabetes mellitus
- Hyperglycemia
- Hypertension
- Hypoglycemic disorder
- Constipation
- Depression
- Dizziness
- Dyspnea
- Headache disorder
- Muscle spasm
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Angioedema
- Cholangitis
- Cholecystitis
- Hypothyroidism
- Pancreatitis
Less Severe
- Abscess
- Steatorrhea
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Lanreotide
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Lanreotide
- Severity Level:
2
- Additional Notes: Insufficient human data; embryocidal in rats and rabbits
Contraindicated
Lanreotide
Mfg does not rec breastfeeding during tx and 6 months after last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Mfg does not rec breastfeeding during tx and 6 months after last dose |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Lanreotide
Renal-Adjust starting dose for moderate to severe renal impairment. Hepatic-Adjust starting dose for moderate to severe hepatic impairment, CrCL < 60 mL/min.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | Y | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Acromegaly | |
| E22.0 | Acromegaly and pituitary gigantism |
| Carcinoid syndrome | |
| E34.0 | Carcinoid syndrome |
| Malignant gastroenteropancreatic neuroendocrine tumor | |
| C25.4 | Malignant neoplasm of endocrine pancreas |
| C7A.01 | Malignant carcinoid tumors of the small intestine |
| C7A.010 | Malignant carcinoid tumor of the duodenum |
| C7A.011 | Malignant carcinoid tumor of the jejunum |
| C7A.012 | Malignant carcinoid tumor of the ileum |
| C7A.019 | Malignant carcinoid tumor of the small intestine, unspecified portion |
| C7A.02 | Malignant carcinoid tumors of the appendix, large intestine, and rectum |
| C7A.020 | Malignant carcinoid tumor of the appendix |
| C7A.021 | Malignant carcinoid tumor of the cecum |
| C7A.022 | Malignant carcinoid tumor of the ascending colon |
| C7A.023 | Malignant carcinoid tumor of the transverse colon |
| C7A.024 | Malignant carcinoid tumor of the descending colon |
| C7A.025 | Malignant carcinoid tumor of the sigmoid colon |
| C7A.026 | Malignant carcinoid tumor of the rectum |
| C7A.029 | Malignant carcinoid tumor of the large intestine, unspecified portion |
| C7A.092 | Malignant carcinoid tumor of the stomach |
| C7A.094 | Malignant carcinoid tumor of the foregut, unspecified |
| C7A.095 | Malignant carcinoid tumor of the midgut, unspecified |
| C7A.096 | Malignant carcinoid tumor of the hindgut, unspecified |
| 0-9 | A-Z |
|---|---|
| C25.4 | Malignant neoplasm of endocrine pancreas |
| C7A.01 | Malignant carcinoid tumors of the small intestine |
| C7A.010 | Malignant carcinoid tumor of the duodenum |
| C7A.011 | Malignant carcinoid tumor of the jejunum |
| C7A.012 | Malignant carcinoid tumor of the ileum |
| C7A.019 | Malignant carcinoid tumor of the small intestine, unspecified portion |
| C7A.02 | Malignant carcinoid tumors of the appendix, large intestine, and rectum |
| C7A.020 | Malignant carcinoid tumor of the appendix |
| C7A.021 | Malignant carcinoid tumor of the cecum |
| C7A.022 | Malignant carcinoid tumor of the ascending colon |
| C7A.023 | Malignant carcinoid tumor of the transverse colon |
| C7A.024 | Malignant carcinoid tumor of the descending colon |
| C7A.025 | Malignant carcinoid tumor of the sigmoid colon |
| C7A.026 | Malignant carcinoid tumor of the rectum |
| C7A.029 | Malignant carcinoid tumor of the large intestine, unspecified portion |
| C7A.092 | Malignant carcinoid tumor of the stomach |
| C7A.094 | Malignant carcinoid tumor of the foregut, unspecified |
| C7A.095 | Malignant carcinoid tumor of the midgut, unspecified |
| C7A.096 | Malignant carcinoid tumor of the hindgut, unspecified |
| E22.0 | Acromegaly and pituitary gigantism |
| E34.0 | Carcinoid syndrome |
Formulary Reference Tool